PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance was -6.04% in last session and finished the day at $22.40. Traded volume was 336,862.00million shares in the last session and the average volume of the stock remained 311.80K shares. PTC Therapeutics, Inc. (NASDAQ:PTCT) insider ownership is 9.00%.

Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s SVP Glenn Goddard unloaded 4,000 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $38.08, for a total value of $152,320.00. Agios Pharmaceuticals Inc (NASDAQ:AGIO) rose 0.91 percent to $35.48 Friday on volume of 442,941.00million shares. The intra-day range of the stock was $31.42 to $36.72. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has a market capitalization of $1.12billion.

On March 28, 2014, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and the U.S. Department of Health and Human Services (“HHS”) mutually agreed to amend the Agreement dated January 3, 2007 between the Company and HHS (the “Agreement”) to extend the Agreement’s current expiration date of March 31, 2014 for 30 days. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock on Apr 04, 2014 reported a decrease of -9.99% to the closing price of $9.10. Its fifty two weeks range is $1.32-$13.33. The total market capitalization recorded $545.54million. The overall volume in the last trading session was 1.24million shares. In its share capital, BCRX has 59.95million outstanding shares.

Research analysts at Brean Capital started coverage on shares of TG Therapeutics Inc (NASDAQ:TGTX) in a report released on Friday, Analyst Ratings Network reports. The firm set a “buy” rating and a $13.00 price target on the stock. On Friday, shares of TG Therapeutics, Inc. (NASDAQ:TGTX) dropped -7.21% to close the day at $6.18. Company return on investment (ROI) is -56.00% and its monthly performance is recorded as -9.52%. TG Therapeutics, Inc. (NASDAQ:TGTX) quarterly revenue growth is 50.73%.